Health X Platform Ltd Q4 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Published 1 Jun 2026 | Healthcare Services | Market Cap: ₹977 Cr
SastaSundar estimates 100% growth in B2C segment for FY '26 compared to FY '25. - RetailerShakti B2B business nearly doubled revenue from INR489 crores in FY '24 to approx. FY '26: Targeting RetailerShakti to achieve positive EBITDA margin (~1% in the last quarter), continuing investment of INR45-50 crores in SastaSundar B2C.
From Health X Platform Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Price
₹301
Market Cap
₹977 Cr
P/E Ratio
508.6
How does Health X Platform Ltd rank in Healthcare Services?
Compare Health X Platform Ltd against every Healthcare Services company this quarter on revenue, margins and earnings-call signals.
Health X Platform Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹346 Cr, net profit ₹0 Cr.
Full financials →📊 Revenue & Sales Performance
- →SastaSundar estimates 100% growth in B2C segment for FY '26 compared to FY '25.
- →RetailerShakti B2B business nearly doubled revenue from INR489 crores in FY '24 to approx. INR941 crores in FY '25.
- →Target positive EBITDA margin of 1% for RetailerShakti by Q4 FY '26.
- →Aim for blended EBITDA margin between 4% to 5% by FY '30, with SastaSundar targeting 7% and RetailerShakti around 4%.
- →Long-term vision to scale rapidly with a highly scalable and sustainable model.
- →Focus on building innovative digital healthcare products and AI-driven tools to enhance customer engagement.
- →Cautious approach advised; company still in startup infancy stage, recommending investors to be patient for at least 5 years.
- →No capital raising planned in next 2-3 years, focusing on self-sufficiency and efficient capital investment.
📈 Profitability & Margins
- →FY '26: Targeting RetailerShakti to achieve positive EBITDA margin (~1% in the last quarter), continuing investment of INR45-50 crores in SastaSundar B2C.
- →FY '30: Aiming for blended EBITDA margin between 4% to 5%, with SastaSundar targeting 7% EBITDA margin and RetailerShakti around 4%.
- →Growth drivers include doubling B2C revenue in FY '26, scaling RetailerShakti network and profitability balance.
- →The business is in startup infancy; investors advised to adopt a long-term view (5 years) due to execution risks and growth phase.
- →Capital efficiency and positive cash flow are emphasized, with no planned capital raising for 2-3 years.
- →Expansion of AI-driven healthcare tools and diagnostic integration expected to enhance customer value and revenue streams.
- →Management prioritizes sustainable growth and profitability over short-term quarterly results.
🏗️ Capital Expenditure Plans
- →SastaSundar plans to invest around INR150 crores primarily in technology, supply chain, and warehouse capabilities over FY '25 and FY '26.
- →In FY '25, INR35 crores were invested in the technology team and advertisement, matching projections.
- →FY '26 projection includes around INR50 crores investment mainly directed towards building the technology platform and AI capabilities.
- →Treasury income will cover about INR50 crores investment in SastaSundar, aiming for self-sufficiency without raising new capital for at least 2-3 years.
- →Capital allocation is cautious, focusing on small-scale experiments with low failure costs for learning.
- →Future investments depend on achieving profitability in RetailerShakti and validation of the SastaSundar B2C model.
- →No plans for capital raising in the near term; management prioritizes building the business over fundraising activities.
💰 Fundraising & Capital Structure
- →SastaSundar Ventures Limited does not project to raise any capital (debt or equity) in the next 2-3 years.
- →The company aims to be self-sufficient and focus fully on building the business without spending management bandwidth on fundraising.
- →Current investments are funded through treasury income and operational cash flows.
- →The company emphasizes capital efficiency and managing growth through existing resources rather than external funding.
- →Any experimentation or innovation is done with small capital to control costs and risks.
- →The management advises investors to be patient over the next 5 years, as the company is still in an early stage with high growth potential but also significant execution risks.
📋 Order Book & Pipeline
Key Metrics
Frequently Asked Questions
What were Health X Platform Ltd Q4 FY25 results?
SastaSundar estimates 100% growth in B2C segment for FY '26 compared to FY '25. - RetailerShakti B2B business nearly doubled revenue from INR489 crores in FY '24 to approx. FY '26: Targeting RetailerShakti to achieve positive EBITDA margin (~1% in the last quarter), continuing investment of INR45-50 crores in SastaSundar B2C.
What is Health X Platform Ltd share price analysis?
Health X Platform Ltd currently shows a neutral. The stock trades at a P/E of 508.6 with a market cap of ₹977 Cr. Investors should review the full earnings analysis for detailed insights.
Is Health X Platform Ltd planning capital expenditure?
SastaSundar plans to invest around INR150 crores primarily in technology, supply chain, and warehouse capabilities over FY '25 and FY '26.
Keep Health X Platform Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.